Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Related Articles by Review for PubMed (Select 21750172)

1.

Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.

Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Søiland H, Gjerde J, Garne JP, Rosenberg CL, Silliman RA, Sørensen HT, Lash TL, Hamilton-Dutoit S.

Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1937-43. doi: 10.1158/1055-9965.EPI-11-0419. Epub 2011 Jul 12.

2.

The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.

Fleeman N, Martin Saborido C, Payne K, Boland A, Dickson R, Dundar Y, Fernández Santander A, Howell S, Newman W, Oyee J, Walley T.

Health Technol Assess. 2011 Sep;15(33):1-102. doi: 10.3310/hta15330. Review.

3.

Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen.

Lazarus P, Blevins-Primeau AS, Zheng Y, Sun D.

Ann N Y Acad Sci. 2009 Feb;1155:99-111. doi: 10.1111/j.1749-6632.2009.04114.x. Review.

4.

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.

Lum DW, Perel P, Hingorani AD, Holmes MV.

PLoS One. 2013 Oct 2;8(10):e76648. doi: 10.1371/journal.pone.0076648. eCollection 2013. Review.

5.

Genotype-guided tamoxifen therapy: time to pause for reflection?

Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S.

Lancet Oncol. 2009 Aug;10(8):825-33. doi: 10.1016/S1470-2045(09)70030-0. Review.

6.

Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.

Singh MS, Francis PA, Michael M.

Breast. 2011 Apr;20(2):111-8. doi: 10.1016/j.breast.2010.11.003. Epub 2010 Dec 24. Review.

PMID:
21185724
7.

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.

Zeng Z, Liu Y, Liu Z, You J, Chen Z, Wang J, Peng Q, Xie L, Li R, Li S, Qin X.

Cancer Chemother Pharmacol. 2013 Aug;72(2):287-303. doi: 10.1007/s00280-013-2195-9. Epub 2013 May 28. Review.

PMID:
23712329
8.

CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance.

Higgins MJ, Stearns V.

Curr Oncol Rep. 2010 Jan;12(1):7-15. doi: 10.1007/s11912-009-0076-5. Review.

PMID:
20425602
9.

Pharmacogenomics of tamoxifen and irinotecan therapies.

Algeciras-Schimnich A, O'Kane DJ, Snozek CL.

Clin Lab Med. 2008 Dec;28(4):553-67. doi: 10.1016/j.cll.2008.05.004. Review.

PMID:
19059062
10.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

PMID:
18705406
11.

Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.

Cronin-Fenton DP, Lash TL.

Expert Rev Clin Pharmacol. 2011 May;4(3):363-77. doi: 10.1586/ecp.11.18. Review.

12.

Toremifene versus tamoxifen for advanced breast cancer.

Mao C, Yang ZY, He BF, Liu S, Zhou JH, Luo RC, Chen Q, Tang JL.

Cochrane Database Syst Rev. 2012 Jul 11;7:CD008926. doi: 10.1002/14651858.CD008926.pub2. Review.

PMID:
22786516
13.

Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.

Stingl JC, Bartels H, Viviani R, Lehmann ML, Brockmöller J.

Pharmacol Ther. 2014 Jan;141(1):92-116. doi: 10.1016/j.pharmthera.2013.09.002. Epub 2013 Sep 27. Review.

PMID:
24076267
14.

Mitochondria: the gateway for tamoxifen-induced liver injury.

Ribeiro MP, Santos AE, Custódio JB.

Toxicology. 2014 Sep 2;323:10-8. doi: 10.1016/j.tox.2014.05.009. Epub 2014 Jun 2. Review.

PMID:
24881593
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk